These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 32388480)

  • 21. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.
    Sharifkashani S; Bafrani MA; Khaboushan AS; Pirzadeh M; Kheirandish A; Yavarpour Bali H; Hessami A; Saghazadeh A; Rezaei N
    Eur J Pharmacol; 2020 Oct; 884():173455. PubMed ID: 32745604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ACE2 and COVID-19 and the resulting ARDS.
    Zhang X; Li S; Niu S
    Postgrad Med J; 2020 Jul; 96(1137):403-407. PubMed ID: 32522846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?
    Aleksova A; Ferro F; Gagno G; Cappelletto C; Santon D; Rossi M; Ippolito G; Zumla A; Beltrami AP; Sinagra G
    J Intern Med; 2020 Oct; 288(4):410-421. PubMed ID: 32459372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).
    Zemlin AE; Wiese OJ
    Ann Clin Biochem; 2020 Sep; 57(5):339-350. PubMed ID: 32369402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
    Malek Mahdavi A
    Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2 Pathogenesis: Imbalance in the Renin-Angiotensin System Favors Lung Fibrosis.
    Delpino MV; Quarleri J
    Front Cell Infect Microbiol; 2020; 10():340. PubMed ID: 32596170
    [No Abstract]   [Full Text] [Related]  

  • 27. Covid-19: the renin-angiotensin system imbalance hypothesis.
    Lanza K; Perez LG; Costa LB; Cordeiro TM; Palmeira VA; Ribeiro VT; Simões E Silva AC
    Clin Sci (Lond); 2020 Jun; 134(11):1259-1264. PubMed ID: 32507883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.
    Chung MK; Karnik S; Saef J; Bergmann C; Barnard J; Lederman MM; Tilton J; Cheng F; Harding CV; Young JB; Mehta N; Cameron SJ; McCrae KR; Schmaier AH; Smith JD; Kalra A; Gebreselassie SK; Thomas G; Hawkins ES; Svensson LG
    EBioMedicine; 2020 Aug; 58():102907. PubMed ID: 32771682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients.
    Zamai L
    Cells; 2020 Jul; 9(7):. PubMed ID: 32708755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
    Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
    J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19.
    Hooper NM; Lambert DW; Turner AJ
    Clin Sci (Lond); 2020 Sep; 134(18):2489-2501. PubMed ID: 32990314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.
    Wu L; O'Kane AM; Peng H; Bi Y; Motriuk-Smith D; Ren J
    Biochem Pharmacol; 2020 Aug; 178():114114. PubMed ID: 32579957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.
    Greco A; Buccheri S; D'Arrigo P; Calderone D; Agnello F; Monte M; Milluzzo RP; Franchina AG; Ingala S; Capodanno D
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):335-337. PubMed ID: 32671399
    [No Abstract]   [Full Text] [Related]  

  • 34. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
    Tseng YH; Yang RC; Lu TS
    Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
    Lubbe L; Cozier GE; Oosthuizen D; Acharya KR; Sturrock ED
    Clin Sci (Lond); 2020 Nov; 134(21):2851-2871. PubMed ID: 33146371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
    Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
    Dtsch Med Wochenschr; 2020 May; 145(10):682-686. PubMed ID: 32323279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renin-angiotensin system and SARS-CoV-2 interaction: underlying mechanisms and potential clinical implications.
    Hrenak J; Zorad S; Simko F
    Gen Physiol Biophys; 2020 May; 39(3):203-204. PubMed ID: 32525813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
    Young MJ; Clyne CD; Chapman KE
    J Endocrinol; 2020 Nov; 247(2):R45-R62. PubMed ID: 32966970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.
    Siniorakis E; Arvanitakis S; Nikolopoulos I; Elkouris M
    mBio; 2020 May; 11(3):. PubMed ID: 32444383
    [No Abstract]   [Full Text] [Related]  

  • 40. Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2.
    Muchtaridi M; Fauzi M; Khairul Ikram NK; Mohd Gazzali A; Wahab HA
    Molecules; 2020 Sep; 25(17):. PubMed ID: 32882868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.